Study endpoints
cardiotoxicity
The primary endpoint was a proportion of patients with hsTnI level more than the cut-off value (> 15.6 ng/L) at the final cycle or 2-week after doxorubicin treatment. Secondary endpoints were changes in hsTnI level, NT-proBNP level, mitochondrial function, LVEF and GLS after doxorubicin treatment. We used troponin-I as the primary outcome since it exhibits a stronger correlation with cardiotoxicity compared to NT-proBNP